i-Inositol是一种参与胰岛素信号转导、细胞骨架转导等一系列生物过程的糖醇。
Cas No.:87-89-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
i-Inositol is a sugar alcohol involved in a series of biological processes such as insulin signal transduction and cytoskeleton transduction. i-Inositol is mainly present in glial cells and plays an osmotic role. i-Inositol can be used in research related to polycystic ovary syndrome, sperm function, and diabetes improvement[1-4].
In vitro, i-Inositol (100nM–10mM) was co-treated with PMA (1–100ng/ml), LPS (0.1–10μg/ml), IFN-γ (150unit/ml), or CsA (0.5–50nM) in RAW 264.7 mouse macrophages for 24 hours. i-Inositol restored taurine transport activity in a dose-dependent manner[5]. i-Inositol (0.02–0.10mg/ml) was used to treat DU-145 prostate cancer cells for 72 hours. i-Inositol significantly reduced cell viability[6].
In vivo, i-Inositol (360mg/kg/day) was orally administered daily to C57 BL/6J mice for 14 days. i-Inositol significantly reduced cadmium-induced serum urea nitrogen and creatinine levels, increased renal glutathione content and glutathione peroxidase activity, decreased tumor necrosis factor-α and inducible nitric oxide synthase expression, reduced monocyte chemoattractant protein-1, kidney injury molecule-1, and inositol oxygenase immunoreactivity, decreased the number of apoptotic cells, and protected kidney morphology[7]. i-Inositol (1.2mg/g/day) was intraperitoneally injected daily into female CD-1 Swiss mice for 15 days. i-Inositol significantly reduced white adipose tissue accumulation and improved insulin sensitivity in the mice[8].
References:
[1] Merviel P, James P, Bouée S, et al. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reprod Health. 2021 Jan 19;18(1):13.
[2] Bizzarri M, Monti N, Piombarolo A, et al. Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review. Nutrients. 2023 Apr 13;15(8):1875.
[3] Benvenga S, Marini HR, Micali A, et al. Protective Effects of Myo-Inositol and Selenium on Cadmium-Induced Thyroid Toxicity in Mice. Nutrients. 2020 Apr 26;12(5):1222.
[4] Long L, Huang Q, Song T, Dai Z. Myo-inositol rescued insulin resistance and dyslipidemia in db/db mice. J Appl Biomed. 2024 Jun;22(2):74-80.
[5] Kim HW, Kim JH, An HS, et al. Myo-inositol restores the inflammation-induced down-regulation of taurine transport by the murine macrophage cell line, RAW 264.7. Life Sci. 2003 Sep 26;73(19):2477-89.
[6] Islam MJ, Muntaha S, Masum MM, et al. Proteomic Analysis of Anticancer Effect of Myo-inositol in Human Prostate Cancer (DU-145) Cell Line. Asian Pac J Cancer Prev. 2024 Dec 1;25(12):4447-4455.
[7] Pallio G, Micali A, Benvenga S, et al. Myo-inositol in the protection from cadmium-induced toxicity in mice kidney: An emerging nutraceutical challenge. Food Chem Toxicol. 2019 Oct;132:110675.
[8] Croze ML, Vella RE, Pillon NJ, et al. Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice. J Nutr Biochem. 2013 Feb;24(2):457-66.
i-Inositol是一种参与胰岛素信号转导、细胞骨架转导等一系列生物过程的糖醇。i-Inositol主要存在于神经胶质细胞中起渗透作用。i-Inositol可用于多囊卵巢综合征、精子功能、糖尿病改善的相关研究[1-4]。
在体外，i-Inositol（100nM–10mM）与PMA（1–100ng/ml）、LPS（0.1–10μg/ml）、IFN-γ（150unit/ml）或CsA（0.5–50nM）共同处理RAW 264.7小鼠巨噬细胞24小时。i-Inositol以剂量依赖的方式恢复牛磺酸转运活性[5]。i-Inositol（0.02–0.10mg/ml）处理DU-145前列腺癌细胞72小时。i-Inositol显著降低细胞活力[6]。
在体内，i-Inositol（360mg/kg/day）每日口服，用于处理C57 BL/6J小鼠14天。i-Inositol显著降低了镉诱导的血清尿素氮和肌酐水平，增加了肾脏谷胱甘肽含量和谷胱甘肽过氧化物酶活性，降低了肿瘤坏死因子-α和诱导型一氧化氮合酶表达，减少了单核细胞趋化蛋白-1、肾损伤分子-1和肌醇加氧酶免疫反应性，减少了凋亡细胞数量，并保护了肾脏形态[7]。i-Inositol（1.2mg/g/day）每日腹腔注射，用于处理雌性CD-1 Swiss小鼠15天。i-Inositol显著减少了小鼠的白色脂肪组织积累并改善了胰岛素敏感性[8]。
| Cell experiment [1]: | |
Cell lines | DU-145 prostate cancer cells (human prostate adenocarcinoma cell line) |
Preparation Method | DU-145 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% sodium pyruvate, and 1% penicillin-streptomycin at 37°C in a humidified incubator with 5% CO₂. The cells were treated with i-Inositol at concentrations ranging from 0.02 to 0.10mg/ml for 72 hours. |
Reaction Conditions | 0.02–0.10mg/ml; 72h |
Applications | i-Inositol significantly reduced DU-145 cell viability in a dose-dependent manner. Proteomic analysis revealed marked differences in protein expression between treated and untreated cells, with suppression of proteins like Annexin A2 and Cofilin-1-A in controls, and upregulation of proteins such as Rho GTPase-activating protein, Apoptotic protease-activating factor 1 (APAF1), and TNF receptor-associated factor 2 (TRAF2) in treated samples, indicating modulation of key signaling pathways involved in tumor suppression and oncogenesis. |
| Animal experiment [2]: | |
Animal models | Female CD-1 Swiss mice |
Preparation Method | Mice were given daily intraperitoneal injection of i-Inositol (1.2mg/g/day) for 15 days. |
Dosage form | 1.2mg/g/day; i.p.; 15 consecutive days |
Applications | i-Inositol treatment significantly reduced white adipose tissue accretion, decreased adipocyte volume, improved glucose tolerance, enhanced insulin sensitivity, increased insulin-induced PKB/Akt phosphorylation in skeletal muscle, reduced plasma non-esterified fatty acids, and increased total plasma antioxidant activity. |
References: | |
| Cas No. | 87-89-8 | SDF | |
| 别名 | 肌醇; myo-Inositol; meso-Inositol | ||
| 化学名 | cyclohexane-1,2,3,4,5,6-hexaol | ||
| Canonical SMILES | OC1C(O)C(O)C(O)C(O)C1O | ||
| 分子式 | C6H12O6 | 分子量 | 180.16 |
| 溶解度 | 9mg/ml in DMSO;≥ 50mg/mL in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.5506 mL | 27.7531 mL | 55.5062 mL |
| 5 mM | 1.1101 mL | 5.5506 mL | 11.1012 mL |
| 10 mM | 555.1 μL | 2.7753 mL | 5.5506 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet